Breaking News

Naobios and Sumagen Achieve Milestone in HIV-1 Vaccine Production

Successfully optimize HIV vaccine candidate for industrial production.

Author Image

By: Charlie Sternberg

Associate Editor

Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of virus-based products, and Sumagen Canada Inc (Sumagen), a Korean-Canadian biotechnology company part of CreoSG Co., Ltd, has announced the production of Sumagen’s HIV-1 vaccine candidate at bench scale.   Sumagen candidate (SAV001) is a genetically modified, whole-killed HIV vaccine which demonstrated both tolerance and safety for human use in phase I...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters